Skip to main content
PMC home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 1997 Sep;89(9):622–628.

Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer.

R C Bergan 1, R G Walls 1, W D Figg 1, N A Dawson 1, D Headlee 1, A Tompkins 1, S M Steinberg 1, E Reed 1
PMCID: PMC2608263  PMID: 9302860

Abstract

African-American males have a higher incidence of prostate cancer than non-African-American males and an overall poorer prognosis. Environmental factors such as socioeconomic status and biological factors such as an increased frequency of androgen receptor mutation have been identified as causal. As androgen ablation therapy is ubiquitous in the treatment of metastatic prostate cancer, little information is available on clinical outcome independent of hormone therapy. Our experience at the Warren G. Magnusson Clinical Center, National Institutes of Health with the anticancer agent, suramin, offers the opportunity to study clinical outcome in patients treated with an agent whose tumoricidal activity is not dependent on androgen receptor function. Clinical outcome was examined retrospectively in 43 patients treated on a single suramin-based protocol and evaluated as a function of ethnic background. No significant difference in time to disease progression or survival was observed between African Americans (n = 4) and the other 39 patients. These findings are consistent with the hypothesis that therapies that work through mechanisms independent of the androgen receptor may result in similar outcomes across ethnic groups.

Full text

PDF
622

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahluwalia B., Jackson M. A., Jones G. W., Williams A. O., Rao M. S., Rajguru S. Blood hormone profiles in prostate cancer patients in high-risk and low-risk populations. Cancer. 1981 Nov 15;48(10):2267–2273. doi: 10.1002/1097-0142(19811115)48:10<2267::aid-cncr2820481023>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  2. Boring C. C., Squires T. S., Tong T. Cancer statistics, 1993. CA Cancer J Clin. 1993 Jan-Feb;43(1):7–26. doi: 10.3322/canjclin.43.1.7. [DOI] [PubMed] [Google Scholar]
  3. Chiarodo A. National Cancer Institute roundtable on prostate cancer: future research directions. Cancer Res. 1991 May 1;51(9):2498–2505. [PubMed] [Google Scholar]
  4. Clayton L. A., Byrd W. M. The African-American cancer crisis, Part I: The problem. J Health Care Poor Underserved. 1993;4(2):83–101. doi: 10.1353/hpu.2010.0299. [DOI] [PubMed] [Google Scholar]
  5. Coetzee G. A., Ross R. K. Re: Prostate cancer and the androgen receptor. J Natl Cancer Inst. 1994 Jun 1;86(11):872–873. doi: 10.1093/jnci/86.11.872. [DOI] [PubMed] [Google Scholar]
  6. Cooper M. R., Lieberman R., La Rocca R. V., Gernt P. R., Weinberger M. S., Headlee D. J., Kohler D. R., Goldspiel B. R., Peck C. C., Myers C. E. Adaptive control with feedback strategies for suramin dosing. Clin Pharmacol Ther. 1992 Jul;52(1):11–23. doi: 10.1038/clpt.1992.97. [DOI] [PubMed] [Google Scholar]
  7. Danesi R., Del Bianchi S., Soldani P., Campagni A., La Rocca R. V., Myers C. E., Paparelli A., Del Tacca M. Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer. 1993 Nov;68(5):932–938. doi: 10.1038/bjc.1993.457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dawson N. A., Cooper M. R., Figg W. D., Headlee D. J., Thibault A., Bergan R. C., Steinberg S. M., Sausville E. A., Myers C. E., Sartor O. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer. 1995 Aug 1;76(3):453–462. doi: 10.1002/1097-0142(19950801)76:3<453::aid-cncr2820760316>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  9. Edwards A., Hammond H. A., Jin L., Caskey C. T., Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics. 1992 Feb;12(2):241–253. doi: 10.1016/0888-7543(92)90371-x. [DOI] [PubMed] [Google Scholar]
  10. Hu D. E., Fan T. P. Suppression of VEGF-induced angiogenesis by the protein tyrosine kinase inhibitor, lavendustin A. Br J Pharmacol. 1995 Jan;114(2):262–268. doi: 10.1111/j.1476-5381.1995.tb13221.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Irvine R. A., Yu M. C., Ross R. K., Coetzee G. A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 1995 May 1;55(9):1937–1940. [PubMed] [Google Scholar]
  12. Jones G. W., Mettlin C., Murphy G. P., Guinan P., Herr H. W., Hussey D. H., Chmiel J. S., Fremgen A. M., Clive R. E., Zuber-Ocwieja K. E. Patterns of care for carcinoma of the prostate gland: results of a national survey of 1984 and 1990. J Am Coll Surg. 1995 May;180(5):545–554. [PubMed] [Google Scholar]
  13. La Rocca R. V., Stein C. A., Myers C. E. Suramin: prototype of a new generation of antitumor compounds. Cancer Cells. 1990 Apr;2(4):106–115. [PubMed] [Google Scholar]
  14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  15. Mettlin C. J., Murphy G. The National Cancer Data Base report on prostate cancer. Cancer. 1994 Sep 1;74(5):1640–1648. doi: 10.1002/1097-0142(19940901)74:5<1640::aid-cncr2820740525>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  16. Moul J. W., Sesterhenn I. A., Connelly R. R., Douglas T., Srivastava S., Mostofi F. K., McLeod D. G. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA. 1995 Oct 25;274(16):1277–1281. [PubMed] [Google Scholar]
  17. Moul J. W., Sesterhenn I. A., Connelly R. R., Douglas T., Srivastava S., Mostofi F. K., McLeod D. G. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA. 1995 Oct 25;274(16):1277–1281. [PubMed] [Google Scholar]
  18. Myers C., Cooper M., Stein C., LaRocca R., Walther M. M., Weiss G., Choyke P., Dawson N., Steinberg S., Uhrich M. M. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol. 1992 Jun;10(6):881–889. doi: 10.1200/JCO.1992.10.6.881. [DOI] [PubMed] [Google Scholar]
  19. Ndubuisi S. C., Kofie V. Y., Andoh J. Y., Schwartz E. M. Black-white differences in the stage at presentation of prostate cancer in the District of Columbia. Urology. 1995 Jul;46(1):71–77. doi: 10.1016/S0090-4295(99)80162-9. [DOI] [PubMed] [Google Scholar]
  20. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1996. CA Cancer J Clin. 1996 Jan-Feb;46(1):5–27. doi: 10.3322/canjclin.46.1.5. [DOI] [PubMed] [Google Scholar]
  21. Powell I. J., Schwartz K., Hussain M. Removal of the financial barrier to health care: does it impact on prostate cancer at presentation and survival? A comparative study between black and white men in a Veterans Affairs system. Urology. 1995 Dec;46(6):825–830. doi: 10.1016/S0090-4295(99)80352-5. [DOI] [PubMed] [Google Scholar]
  22. Ross R., Bernstein L., Judd H., Hanisch R., Pike M., Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst. 1986 Jan;76(1):45–48. [PubMed] [Google Scholar]
  23. Sartor O., Cooper M., Weinberger M., Headlee D., Thibault A., Tompkins A., Steinberg S., Figg W. D., Linehan W. M., Myers C. E. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J Natl Cancer Inst. 1994 Feb 2;86(3):222–227. doi: 10.1093/jnci/86.3.222. [DOI] [PubMed] [Google Scholar]
  24. Schapira M. M., McAuliffe T. L., Nattinger A. B. Treatment of localized prostate cancer in African-American compared with Caucasian men. Less use of aggressive therapy for comparable disease. Med Care. 1995 Nov;33(11):1079–1088. doi: 10.1097/00005650-199511000-00002. [DOI] [PubMed] [Google Scholar]
  25. Schoenberg M. P., Hakimi J. M., Wang S., Bova G. S., Epstein J. I., Fischbeck K. H., Isaacs W. B., Walsh P. C., Barrack E. R. Microsatellite mutation (CAG24-->18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun. 1994 Jan 14;198(1):74–80. doi: 10.1006/bbrc.1994.1011. [DOI] [PubMed] [Google Scholar]
  26. Schrell U. M., Gauer S., Kiesewetter F., Bickel A., Hren J., Adams E. F., Fahlbusch R. Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop. J Neurosurg. 1995 Apr;82(4):600–607. doi: 10.3171/jns.1995.82.4.0600. [DOI] [PubMed] [Google Scholar]
  27. Veldscholte J., Ris-Stalpers C., Kuiper G. G., Jenster G., Berrevoets C., Claassen E., van Rooij H. C., Trapman J., Brinkmann A. O., Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 1990 Dec 14;173(2):534–540. doi: 10.1016/s0006-291x(05)80067-1. [DOI] [PubMed] [Google Scholar]
  28. Vijayakumar S., Karrison T., Weichselbaum R. R., Chan S., Quadri S. F., Awan A. M. Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidemiol Biomarkers Prev. 1992 Nov-Dec;1(7):541–545. [PubMed] [Google Scholar]
  29. Wade T. P., Kasid A., Stein C. A., LaRocca R. V., Sargent E. R., Gomella L. G., Myers C. E., Linehan W. M. Suramin interference with transforming growth factor-beta inhibition of human renal cell carcinoma in culture. J Surg Res. 1992 Aug;53(2):195–198. doi: 10.1016/0022-4804(92)90034-w. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES